Ert Batten Brineura denied as experimental or investigational by Cigna?

Cigna's specific coverage criteria for ert batten brineura are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Denies Cerliponase Alfa (Brineura) as Experimental

Cigna may classify cerliponase alfa (Brineura) as experimental or investigational by applying its standard evidence-review criteria to an ultra-rare disease drug whose clinical evidence base — while sufficient for FDA approval — is necessarily smaller than for common conditions. The drug is approved by the FDA for a specific inherited neurological disorder (CLN2 Batten disease) affecting a very small population, and insurers sometimes apply higher evidentiary bars or fail to update their medical policies promptly following approval of rare-disease therapies.

## Why This Denial Is Appealable

FDA approval under the agency's rigorous review process — which for rare-disease drugs may include Breakthrough Therapy Designation or accelerated pathways — is the accepted standard for establishing that a drug is not experimental for its approved indication. If Brineura is prescribed for its FDA-approved CLN2 indication, the experimental label is legally and clinically contestable. Relevant professional organizations focused on neuronal ceroid lipofuscinoses and pediatric neurological diseases support evidence-based use of this therapy in appropriate patients.

## Federal Appeal Framework

• Internal appeal: File within the deadline on your denial notice. Cigna must respond within 60 days (post-service) or 30 days (pre-service) for standard review.
• Expedited appeal: Request within 72 hours for urgent clinical situations — particularly important given the rapid neurological progression of CLN2.
• External review (ACA §2719 / ERISA §503): After internal exhaustion, file for independent external review within approximately four months. The IRO's determination is binding on Cigna. External review is especially powerful for experimental denials — IROs apply objective evidence standards rather than insurer-specific policies.
• State insurance commissioner: If Cigna's policy appears to conflict with state rare-disease coverage mandates, a regulatory complaint can run in parallel with the appeal.

## Appeal Process and Timeline

1. Obtain Cigna's specific clinical policy used to classify Brineura as experimental and identify the exact evidence criteria applied. 2. Confirm the FDA-approval status and indication; obtain the current FDA prescribing label. 3. Have the treating specialist — a physician experienced in CLN2 management — write a detailed letter establishing: (a) confirmed CLN2 diagnosis, (b) that the use is within the FDA-approved indication, (c) that the FDA approval itself constitutes the evidence standard, and (d) the urgency given disease progression. 4. Identify whether Cigna's policy references any medical compendia or peer-reviewed literature standards for rare-disease coverage — and document that Brineura meets them. 5. Submit internal appeal; file external review immediately upon internal denial.

## Documentation to Gather

• Confirmed CLN2 genetic and biochemical diagnosis: Genetic test results, enzyme activity documentation, neurological evaluation — from the chart.
• FDA prescribing label: Demonstrating approved indication, FDA review pathway, and that the prescribed use is on-label.
• Treating specialist letter: Linking diagnosis to indication, establishing urgency, and addressing the specific evidence criteria in Cigna's policy.
• Disease natural-history documentation: Chart notes and neurological assessments reflecting functional trajectory — contextualizing why treatment delay is harmful.
• Relevant guideline organization reference: Citing the applicable professional society's guidance on CLN2 management (without quoting specific numbers from it).

## Criteria-Mapping Structure

Copy each criterion from Cigna's experimental/investigational coverage policy into your appeal. Under each, document the specific evidence satisfying it — FDA label text, prescriber attestation, or literature reference as appropriate. For the core experimental criterion, lead with FDA approval status and the drug's regulatory pathway as primary evidence. This point-by-point structure is critical for external review, where IRO reviewers evaluate each criterion independently.